Edgewise Therapeutics Inc

Edgewise Therapeutics develops muscle-targeting therapeutics for muscular dystrophies and cardiac conditions. Its lead candidate sevasemten is a first-in-class oral fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage. Long-term Phase 2 data demonstrated sustained functional stabilization through 3.5 years in Becker muscular dystrophy, and the FOX Phase 2 trial showed potential to reduce functional decline in Duchenne patients previously treated with gene therapy. Edgewise plans to initiate a pivotal Phase 3 study in 2026. EDG-7500, a novel cardiac sarcomere modulator for hypertrophic cardiomyopathy, has Phase 2 results anticipated in the first half of 2026. Both programs required preclinical animal pharmacology and toxicology studies: sevasemten's muscle-protective mechanism was established in dystrophic animal models, and EDG-7500 underwent cardiac safety testing in animal models before clinical development.